On the 28th – 30th May, NDA will contribute to a 3 day Course in the Development of Biological Drugs in Stockholm and/or distance, in conjunction with Sweden Bio and Swedish Academy of Pharmaceutical Sciences.
Olga Björklund, Senior Consultant, NDA Group is on the programme committee and has been invited to give the opening presentation, Paul Chamberlain, Immunogenicity specialist, NDA Advisory Board will be presenting on Immunogenicity, Ira Palminger Hallen, Senior Consultant will cover Biosimilars – preclinical and clinical aspects, and Terese Johansson Regulatory Affairs Consultant, will give an overview on Advance Therapy Medicinal Products (ATMPs).
The three-day course will provide insights into all components that should be addressed to effectively develop new biologics, from discovery to product launch.
WHO SHOULD ATTEND?
The course is aimed for those involved in drug development of biologics (eg in small and medium-sized companies), and need a comprehensive picture of the complex development chain.
The course will not only be offered as a traditional course but also as a distance course. Those who choose to attend online will have access to all streamed lectures for 1 month.
Click here to find out more about the event and to register.